A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market
A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market
Launch of Novel Immunoglobulin Products and Increasing Awareness of Therapeutic Options to Drive Double-digit Market Growth
08-Dec-2015
Asia Pacific
$6,000.00
Special Price $4,500.00 save 25 %
Description
The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges.
Table of Contents
Executive Summary
Recent Market Developments
Key M&As and Partnership Assessment
Companies to Watch
Methodology and Scope
Market Background—Segmentation
Market Background—Segmentation (continued)
Market Background—Segmentation (continued)
Market Segmentation
Market Segmentation (continued)
Market Forecasting
Competitive Landscape—Human Plasma-derived Therapeutics: Marketed Products
Competitive Landscape—Human Plasma-derived Therapeutics Market: Pipeline Products
Competitive Landscape—Count of Marketed and Pipeline Products
Competitive Landscape—Key Clinical Trials
Marketed Products Synopsis—Albumin
Marketed Products Synopsis—Other Haematologicals
Marketed Products Synopsis—Other Haematologicals (continued)
Marketed Products Synopsis—Coagulation Factors
Marketed Products Synopsis—Coagulation Factors (continued)
Marketed Products Synopsis—Coagulation Factors (continued)
Marketed Products Synopsis—Coagulation Factors (continued)
Marketed Products Synopsis—Immunoglobulins
Marketed Products Synopsis—Immunoglobulins (continued)
Marketed Products Synopsis—Immunoglobulins (continued)
Marketed Products Synopsis—Immunoglobulins (continued)
Marketed Products Synopsis—Immunoglobulins (continued)
Marketed Products Synopsis—Immunoglobulins (continued)
Pipeline Analysis—Approved
Pipeline Analysis—Phase 3
Pipeline Analysis—Phase 3 (continued)
Pipeline Analysis—Phase 2
Pipeline Analysis—Phase 1
Product Dashboard—ResusixTM, Entegrion, Inc.
Product Dashboard—CINRYZE® (new formulation), Shire
Product Dashboard—BIOSTATE® (new formulation), CSL Behring
Product Dashboard—Gammagard, Baxter
Conclusions and Recommendations
Legal Disclaimer
Plasma—Overview
Plasma—Overview (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Sumedha Pareek |
WIP Number | MAEC-01-00-00-00 |
Is Prebook | No |